CLAIMS

1. A compound of formula(I)



(I)

wherein

R represents halogen, C_{1-4} alkyl, cyano, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy;

R_1 represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R_1 represents a 4, 5 or 6 membered heterocyclic group, wherein saids 5 or 6 membered heteroaryl or the 4, 5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from $(CH_2)_pR_6$, wherein p is zero or an integer from 1 to 4 and R_6 is selected from:

halogen,
C_{1-4}alkoxy,
C_{1-4}alkyl,
C_{3-7}cycloalkyl,
C_{1-4} alkyl optionally substituted by halogen, cyano or C_{1-4} alkoxy,
hydroxy,
cyano,
nitro,
trifluoromethyl,
carboxy,
$NH(C_{1-4}$ alkyl),
$N(C_{1-4}$ alkyl$)_2$
$NH(C_{3-7}$ cycloalkyl),
$N(C_{1-4}$ alkyl$)(C_{3-7}$ cycloalkyl);
$NH(C_{1-4}$alkylOC_{1-4}alkoxy),
$OC(O)NR_7R_8$,
$NR_8C(O)$ R_7 or
$C(O)NR_7R_8$;

R_2 represents hydrogen, or C_{1-4} alkyl ;

R_3 and R_4 independently represent hydrogen, C_{1-4} alkyl or R_3 together with R_4 represents C_{3-7} cycloalkyl;

R_5 represents trifluoromethyl, $S(O)_qC_{1-4}$ alkyl, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethoxy, halogen or cyano;
R_7 and R_8 independently represent hydrogen, C_{1-4} alkyl or C_{3-7} cycloalkyl;
L is a single or a double bond;
n is an integer from 1 to 3;
m is zero or an integer from 1 to 3;
q is zero or an integer from 1 to 2;
provided that
a) when L is a double bond, R_1 is not an optionally substituted 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms;
b) the group R_1 is linked to the carbon atom shown as * via a carbon atom;
and
c) when the heteroatom contained in the group R_1 is substituted, p is not zero;
and pharmaceutically acceptable salts and solvates thereof.

2. A compound as claimed in claim 1 wherein R is halogen (e.g. fluorine or chlorine) and/or a C_{1-4} alkyl (e.g. methyl) group and n is an integer from 1 to 2.

3. A compound as claimed in claim 1 or claim 2 wherein R_5 is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is an integer from 1 to 2.

4. A compound as claimed in any of claims 1 to 3 wherein R_1 is piperidyl, morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl.

5. A compound as claimed in any of claims 1 to 4 wherein R is halogen (e.g. fluorine or chlorine) and/or a C_{1-4} alkyl (e.g. methyl) group and n is an integer from 1 to 2; R_1 is piperidyl, 2-morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl and wherein R_1 is optionally substituted by one or two groups selected from halogen (e.g fluorine), C_{1-4} alkyl (e.g. methyl) or ethylC_{1-4} alkoxy; R_2 and R_3 are independently hydrogen or methyl; R_4 is hydrogen, methyl or together with R_3 is cyclopropyl and R_5 is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is preferably an integer from 1 to 2.

6. A compound selected from:
N-(3,5-Bis-trifluoromethyl-benzyl)-3-(4-fluoro-phenyl)-*N*-methyl-3-piperidin-4-yl-propionamide;
N-(3,5-Dichloro-benzyl)-3-(4-fluoro-phenyl)-*N*-methyl-3-piperidin-4-yl-propionamide;
N-[1-(3,5-Dichloro-phenyl)-ethyl]-3-(4-fluoro-phenyl)-*N*-methyl-3-piperidin-4-yl-propionamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-3-(4-fluoro-phenyl)-*N*-methyl-3-[1-(2-methoxyethyl)-piperidin-4-yl]-propionamide;
N-(3,5-Dichloro-benzyl)-3-(4-fluoro-phenyl)-3-(4-fluoro-piperidin-4-yl)-*N*-methyl-proprionamide;
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-{1-[2-(methyloxy)ethyl]-4-piperidinyl}propionamide*N*-{-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propanamide;
N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-3-(4-fluorophenyl)-3-(4-piperidinyl)propionamide;
N-{[3-bromo-4-(methyloxy)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;
N-[(3,5-dimethylphenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;
N-[(3,4-dibromophenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;
N-[(3-fluoro-2-methylphenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;
N-{[2-chloro-3-(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide;
N-{-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-{-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(2,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-{-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-[(3,5-dibromophenyl)methyl]-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-[(3,5-dibromophenyl)methyl]-3-(3,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
3-(4-chlorophenyl)-*N*-[(3,5-dibromophenyl)methyl]-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide;
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(3-piperidinylidene)propionamide;
N-[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinylidene)propionamide;
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluoro-2-methylphenyl)-*N*-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)propionamide;
N-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluoro-2-methylphenyl)-*N*-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)propionamide;
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(3-pyrrolidinyl)propionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(3-fluoro-3-piperidinyl)-*N*-methylpropionamide;
N-{-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(2-morpholinyl)propionamide;
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(3-piperidinyl)propionamide;
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-pyridinyl)propionamide;
and enantiomers, diastereiosomers, pharmaceutically acceptable salts(e.g hydrochloride) and solvates thereof.

7. A compound selected from
N-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide(diastereoisomer 1);
N-{(1*S*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide (diastereoisomer 2);
N-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide (diastereoisomer 1;
N-[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide (enantiomer 2);
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(3-fluoro-3-piperidinyl)-*N*-methylpropionamide (diastereoisomer A);
and pharmaceutically acceptable salts(e.g hydrochloride) and solvates thereof.

8. A process for the preparation of a compound as claimed in claim 1 which comprises reacting an activated derivative of the carboxylic acid of formula (II) wherein R_1 has the meaning previously defined or is a protected group thereof, with amine (III)



(II)



(III)

wherein R_2 is C_{1-4} alkyl or a nitrogen protecting group, followed where necessary by removal of any protecting group.

9. A compound as claimed in any claims 1 to 7 for use in therapy.

10. The use of a compound as claimed in any claims 1 to 7 in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins (including

substance P and other neurokinins) and/or by selective inhibition of the serotonin reuptake transporter protein.

11. The use of a compound as claimed in any claims 1 to 7 in the treatment of conditions mediated by tachykinins (including substance P and other neurokinins) and/or by selective inhibition of the serotonin reuptake transporter protein.

12. A pharmaceutical composition comprising a compound as claimed in any claims 1 to 7 in admixture with one or more pharmaceutically acceptable carriers or excipients.

13. A method for the treatment of a mammal, including man, in particular in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins and/or by selective inhibition of the serotonin reuptake transporter protein comprising administration of an effective amount of a compound of formula (I) as claimed in any claims 1 to 7.